Nasus Pharma (NSRX) Reiterated at Market Outperform by Citizens Jun 11, 2026 05:15AM
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron Jun 9, 2026 08:01AM
RedChip's Biotech Virtual Investor Conference Replays Now Available Apr 21, 2026 03:00PM
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms Apr 7, 2026 11:00AM
Nasus Pharma Ltd (NSRX) PT Lowered to $18 at Citizens: NS002 Likely Best-in-Class Mar 26, 2026 04:44AM


Dec 22, 2025 08:00AM Nasus Pharma outlines 2026 clinical milestones for NS002 epinephrine
Dec 18, 2025 02:38AM Citizens Starts Nasus Pharma Ltd (NSRX) at Market Outperform
Oct 8, 2025 08:04AM Nasus Pharma expands Aptar partnership for NS002 epinephrine development
Sep 29, 2025 01:54AM Laidlaw Starts Nasus Pharma Ltd (NSRX) at Buy
Aug 13, 2025 10:16AM Nasus Pharma (NSRX) Opens At $8, IPO Priced At $8
Jul 28, 2025 09:56AM Nasus Pharma (NSRX) Files for 1.25M Share IPO at $8-$10/sh
Jul 9, 2025 04:01PM Nasus Pharma (NSRX) Files for 1M Share IPO at $10-$12/sh